ਗੁਰਦੇ-ਉਤਪਾਦਕ ਪ੍ਰੋਟੀਜ਼ ਜੋ ਪਲਾਜ਼ਮਿਨ ਵਿੱਚ ਬਦਲਦੇ ਹਨ ਅਤੇ ਇਸ ਲਈ ਛੇਤੀ ਫਾਈਬਰਿਨੋਲਿਸਿਸ ਪਲਾਜ਼ਮਿਨੋਜਨ,

urokinase's Usage Examples:

"RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer.

uPAR was originally identified as a saturable binding site for urokinase (also known as uPA) on the cell surface.

Thus, PAI can be said to inhibit the serine proteases tPA and uPA/urokinase, and hence is an inhibitor of fibrinolysis, the physiological process that degrades blood clots.

disorder is characterized by large amounts of the fibrinolytic enzyme urokinase-type plasminogen activator (uPA) in platelets.

varying number of copies in some plasma proteins including prothrombin and urokinase-type plasminogen activator, which are serine proteases belonging to MEROPS.

Function PAI-1's main function entails the inhibition of urokinase plasminogen activator (uPA), an enzyme responsible for the cleavage of plasminogen to form plasmin.

Tranexamic acid also directly inhibits the activity of plasmin with weak potency (IC50 87 mM), and it can block the active-site of urokinase plasminogen activator (uPA) with high specificity (Ki 2 mM) among all the serine proteases.

Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals.

of blood clots that cannot be dissolved by other compound, such as streptokinase and urokinase.

Tissue plasminogen activator (t-PA) and urokinase are the agents that convert plasminogen to the active plasmin, thus allowing.

inhibitor of tissue plasminogen activator and urokinase is plasminogen activator inhibitor-1 (PAI-1).

The human urokinase protein.

serpin superfamily, is a coagulation factor that inactivates tPA and urokinase.